卡维地洛在不稳定型心绞痛患者中的应用  

Application of carvedilol in the patients with unstable angina pectoris.

作　　者：毕桂泉[1] 赵季红[1] 李春华[1] 王丽红[1] 哈玲梅[1] 

机构地区：[1]天津武警医学院附属医院,300162

出　　处：《现代医药卫生》2002年第3期172-173,共2页Journal of Modern Medicine & Health

摘　　要：目的 :评价第三代 β受体阻滞剂卡维地洛治疗不稳定型心绞痛 (UAP)的临床疗效。方法 :选择UAP患者130例 ,随机分为卡维地洛治疗组 (n=68)和倍他乐克对照组 (n=62) ,观察用药4周后的临床治疗有效率以及心肌耗氧量 (RPP)。结果 :(1)治疗组临床总有效率明显高于对照组 ,为94 11 %、80 64% (P<0 05)。 (2)治疗组RPP明显减少 ,用药前后分别为1486±233Kpa·次/分、1322±211Kpa·次/分 (P<0 05) ;而对照组无明显差异 ,用药前后为1500±270Kpa·次/分、1499±115Kpa·次/分 (P>0 05)。(3)治疗组较对照组心血管危险事件发生率明显降低 (P<0 05)。结论 :卡维地洛具有α1 受体阻滞作用和 β-肾上腺素能受体阻滞作用 ,临床治疗UAP疗效显著。Objective:To evaluate the clinical effect of Carvedilol of the third generation β-receptor blocker for treating unstable angina pectoris(UAP).Methods:130 cases of UAP were randomly divided into two groups.68 cases in the treatment group were treated with carvedilol,62 cases in the control group were given with Betaxolol.The effective rate of clinical treatment and the rate pressure product(RPP)were observed after treatment for 4 weeks.Results:(1)The total effective rate of the treatment group was significant higher than that in the control group(94.11% VS 80.64%,P<0 05).(2)The RPP of the treatment group was significantly decreasing,the data around the treatment were 1486±223Kpa.times/min and 1322±211Kpa.times/min respectively(P<0.05),but there was no significant difference in the control group,the data around the treatment were 1500±230Kpa.times/min and 1499±115Kpa.times/min respectively(P>0.05).(3)The incidence of cardiovascular danger in the treatment group was significant lower than that of the control group(P<0.05).Conclusion:Carvedilol has block role of α1-receptor and β-adrenergic receptor and its clinical effect for treating unstable angina pectoris is significant.

关 键 词：Β-肾上腺素能受体阻滞剂 卡维地洛 不稳定型心绞痛 治疗 

分 类 号：R541.4[医药卫生—心血管疾病]